Changing the course of autoimmune disease

Inspired by patients. Driven to make an impact.

Latest News

December 5, 2022 • 4:05pm EST

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read Press Release View All News

November 30, 2022 • 4:05pm EST

Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

Read Press Release View All News

November 3, 2022 • 6:00am EDT

Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results

Read Press Release View All News